Clinical Digest: A Comprehensive Review of Recent Eli Lilly Clinical Trials (2026-04)
This compilation provides an overview of Eli Lilly‘s recent clinical trial activity, encompassing up to 200 of their latest trials. Alongside these trials are potentially related publications, patents, and grant funding, which may include work from Eli Lilly or other entities exploring similar therapeutic areas. This resource aims to offer researchers, clinicians, investors, and the broader public insights into Eli Lilly’s current research and development pipeline. By presenting clinical trial details alongside related intellectual property and financial backing (regardless of origin), this compilation facilitates a broader understanding of Eli Lilly’s strategic focus and how it potentially compares to direct and indirect competitors in these therapeutic spaces. This information can be valuable for identifying emerging trends in drug development, assessing the commercial potential of specific research programs, and understanding the broader landscape of scientific contributions related to Eli Lilly’s clinical trials. (Last updated on: 2026-04-05)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: A Comprehensive Review of Recent Eli Lilly Clinical Trials (2026-04)
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | A Phase 1 Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of LY4060874 in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 18 study visits. |
ELI LILLY | 2026-04-03 |
| 2 | A Phase 1 Study of LY3200882 in Patients With Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors. |
ELI LILLY | 2026-04-03 |
| 3 | EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With An Increased Risk of Recurrence PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years. |
ELI LILLY | 2026-04-02 |
| 4 | A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 weeks of treatment and may include up to 21 visits. |
MANREET KAUR; | 2026-04-01 |
| 5 | A Phase 1, Open-label, Randomized, Four-way Crossover Study to Assess The Relative Bioavailability of Two Phase 3 LY4100511 (DC-853) Tablet Formulations Compared With The Phase 2 LY4100511(DC-853) Tablet Formulation, With and Without A Proton Pump Inhibitor in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations. |
ELI LILLY | 2026-04-01 |
| 6 | NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening. |
ELI LILLY | 2026-03-31 |
| 7 | An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate The Safety and Efficacy of LY3541860 Compared to Placebo in Slowing The Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up. |
ELI LILLY | 2026-03-30 |
| 8 | A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for The Treatment of Chronic Pain PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing. |
DAVID DEATKINE; | 2026-03-27 |
| 9 | A Master Protocol to Investigate The Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes). |
JALAL ABBAS; | 2026-03-27 |
| 10 | Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer’s disease. The study duration including screening and follow-up is up to 93 weeks. |
PAUL BIRD; | 2026-03-27 |
| 11 | A Phase 2, Double-Blind, Proof of Concept Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up. |
ELI LILLY | 2026-03-27 |
| 12 | Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for The Treatment of Diabetic Peripheral Neuropathic Pain PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to test the safety and efficacy of study drug LY4065967 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain. |
DAVID DEATKINE; | 2026-03-27 |
| 13 | A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits. |
HUGH COLEMAN; | 2026-03-27 |
| 14 | A Phase 1 Study to Further Investigate The Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of LY4268989 (MORF-057) in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the body’s absorption and processing of the study drug, the study drug’s effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants |
ELI LILLY | 2026-03-27 |
| 15 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks. |
ANDREA STECK; | 2026-03-27 |
| 16 | An Open-label, Multicenter Study of LY4050784, A Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts – phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years. |
ELI LILLY | 2026-03-27 |
| 17 | A Study of LOXO-783 Administered As Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With A PIK3CA H1047R Mutation PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse. |
ELI LILLY | 2026-03-27 |
| 18 | A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate The Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer’s Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part. |
STEVEN REYNOLDS; | 2026-03-27 |
| 19 | A Master Protocol for A Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate The Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn’s disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continued Access Period. |
SOFIA VERSTRAETE; | 2026-03-27 |
| 20 | CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts. |
GREGORY FRIEDMAN; | 2026-03-27 |
| 21 | A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn’s disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period up to 16 weeks. The study will last about 74 weeks and may include up to 19 visits. |
DAVID ZIRING; | 2026-03-27 |
| 22 | A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 Mg and 4.5 Mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months. |
SUNIL SINHA; | 2026-03-27 |
| 23 | SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab Vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum Vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing. |
MARSHALL SCHREEDER; | 2026-03-25 |
| 24 | A Phase 3b, Randomized Controlled Study to Evaluate The Efficacy and Safety of Tirzepatide Once Weekly 5 Mg And/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction. |
ELI LILLY | 2026-03-25 |
| 25 | A Phase 2 Multicenter, Double-Blind, Parallel-Arm Study to Investigate The Efficacy and Safety of Adjunctive Treatment With Brenipatide in Adult Participants With Schizophrenia (RENEW-Scz-1) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment period will last a maximum of 12 months, and the follow up period will last approximately 2 months. The length of time of your study participation may last up to approximately 15 months. |
LESLIE SMITH; | 2026-03-25 |
| 26 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate The Effect of Retatrutide on The Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 Kg/m2 and Atherosclerotic Cardiovascular Disease And/or Chronic Kidney Disease PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor. |
ELI LILLY | 2026-03-24 |
| 27 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Effect of Lepodisiran on The Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for A First Cardiovascular Event – ACCLAIM-Lp(a) PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema. |
ELI LILLY | 2026-03-24 |
| 28 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Effect of Muvalaplin on The Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had A Prior Atherosclerotic Cardiovascular Event or Are at Risk for A First Atherosclerotic Cardiovascular Event PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. |
SUNILDAT MAHESHWARI; | 2026-03-24 |
| 29 | A Master Protocol for A Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA’s complete. |
YESSICA SACHDEVA; | 2026-03-24 |
| 30 | A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing The Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer – SUNRAY-02 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant. |
JORGE DIAZ; | 2026-03-24 |
| 31 | A Master Protocol to Investigate The Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight. |
DAVID HOTCHKISS; | 2026-03-24 |
| 32 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks. |
HEMANT PANDEY; | 2026-03-24 |
| 33 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate The Efficacy and Safety of Lebrikizumab/LY3650150 in Participants With Chronic Rhinosinusitis With Nasal Polyps on Background Intranasal Corticosteroids PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months. |
WEILY SOONG; | 2026-03-24 |
| 34 | Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years. |
ANITA MAZLOOM; | 2026-03-24 |
| 35 | Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for The Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention. |
BLANCA OZUNA; | 2026-03-24 |
| 36 | A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment. |
PAUL LAMB; | 2026-03-24 |
| 37 | A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks. |
PAUL LAMB; | 2026-03-24 |
| 38 | A Phase 1a/1b Study of LY4052031, An Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts – phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years. |
ELI LILLY | 2026-03-24 |
| 39 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate The Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months. |
SOHEIL HEKMAT; | 2026-03-24 |
| 40 | A Master Protocol for A Randomized, Controlled, Clinical Platform Trial to Investigate The Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants With Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants. |
CAREY CHRONIS; | 2026-03-24 |
| 41 | A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond. |
ELI LILLY | 2026-03-24 |
| 42 | A Single Dose Study to Evaluate The Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days. |
ELI LILLY | 2026-03-24 |
| 43 | A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate The Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Major Depressive Disorder (RENEW-MDD 1) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months. The duration of study participation may vary and may be shortened if depression symptoms worsen or if withdrawal from the study occurs for any reason. |
ARJUN REYES; | 2026-03-23 |
| 44 | FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse. |
ELI LILLY | 2026-03-23 |
| 45 | A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks. |
ELI LILLY | 2026-03-23 |
| 46 | A Phase 1, Multicenter, Randomized, Placebo-Controlled, Participant-Blind, Single-Ascending Dose Study of LY4298445 in Healthy Participants and An Open-Label Single-Ascending Dose and Multiple-Ascending Dose Study of LY4298445 in Participants With Systemic Lupus Erythematosus or Rheumatoid Arthritis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks. |
GLORIA WONG; | 2026-03-23 |
| 47 | A Phase 1, Multicenter, Sequential-Design, Single-Dose, Open-Label Study of Lepodisiran in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic Impairment PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants. The study will last up to approximately 9 weeks, excluding screening. |
ALEXANDER PREZIOSO; | 2026-03-23 |
| 48 | A Phase 1, Open-Label, Fixed-Sequence Study to Investigate The Effect of Fluconazole on The Pharmacokinetics of Olomorasib (LY3537982) in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study in healthy participants is to determine the effect of fluconazole on the amount of study drug that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 7 weeks and will require 12 overnight stays in the research center. |
ELI LILLY | 2026-03-23 |
| 49 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate The Effect of Orforglipron on The Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease And/or Chronic Kidney Disease PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years. |
DANIEL VOGEL; | 2026-03-20 |
| 50 | A Master Protocol for A Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression. Once the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study. |
ADISESHA REDDY; | 2026-03-20 |
| 51 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years. |
MOHAMMAD ARYANPURE; | 2026-03-20 |
| 52 | A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate The Efficacy and Safety of Brenipatide Compared With Placebo for The Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks. |
JAMES SULLIVAN; | 2026-03-20 |
| 53 | A Master Protocol to Investigate The Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up. |
GABRIELA HALDER; | 2026-03-20 |
| 54 | FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no longer responds to platinum-based treatments (a type of chemotherapy). Part B looks at participants whose cancer still responds to platinum-based treatments. The researchers want to find out if Sofetabart Mipitecan works better than the usual treatments that doctors use now and to better understand how safe it is. Each participant’s time in the study will depend on how they respond to the treatment. |
REBECCA AREND; | 2026-03-20 |
| 55 | A Study to Investigate The Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks. |
CHRISTOPHER DEGROAT; | 2026-03-20 |
| 56 | A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate The Efficacy and Safety of Brenipatide Compared With Placebo for The Treatment of Adult Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks. |
JAMES SULLIVAN; | 2026-03-20 |
| 57 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks. |
NOVA LAW; | 2026-03-20 |
| 58 | A Phase 3 Study to Investigate The Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of The Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks. |
LOUISE TABER; | 2026-03-20 |
| 59 | A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate The Efficacy and Safety of Brenipatide Compared With Placebo for The Treatment of Adult Participants With Uncontrolled Moderate to Severe Asthma PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods. |
WILLIAM REEDY; | 2026-03-20 |
| 60 | A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate The Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks. |
RANDALL QUINN; | 2026-03-20 |
| 61 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With A CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With A PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects. |
STEVEN LIU; | 2026-03-20 |
| 62 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With A Weekly Incretin, With and Without Type 2 Diabetes PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks. |
NOVA LAW; | 2026-03-20 |
| 63 | A Phase 3b Study to Investigate The Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks. |
LOUISE TABER; | 2026-03-20 |
| 64 | A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate The Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening. |
HARRY STUDDARD; | 2026-03-20 |
| 65 | A Phase 3b Study to Investigate The Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits. |
JACK VU; | 2026-03-20 |
| 66 | A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3549492 Once Daily Compared With Placebo in Adult Participants With Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year. |
ELI LILLY | 2026-03-20 |
| 67 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years. |
LARRY DEEB; | 2026-03-20 |
| 68 | A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate The Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment. |
CONNIE HSU; | 2026-03-20 |
| 69 | A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years. |
ELI LILLY | 2026-03-20 |
| 70 | A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, A GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced breast, colorectal, prostate, and endometrial cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses. |
ELI LILLY | 2026-03-20 |
| 71 | A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate The Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC), compared with placebo plus SoC in delaying the worsening of bipolar disorder symptoms. The trial is divided into three periods as follows: Screening period that will last approximately 1 month, treatment period that will last a minimum of 6 months, and the follow up period that will last approximately 2 months. The duration of study participation may vary and may be shortened if bipolar symptoms worsen or if withdrawal from the study occurs for any reason. |
GUSTAVO ALVA; | 2026-03-20 |
| 72 | A Single- and Multiple-Ascending Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson’s disease. |
STEVEN REYNOLDS; | 2026-03-20 |
| 73 | A Phase 2, Multicenter, Randomized, Double-Blind Study to Investigate The Efficacy and Safety of Brenipatide Compared With Placebo for Reduction in Risk of Relapse to Cigarette Smoking in Adults (RENEW-Smk-1) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period. . |
TIMOTHY COOK; | 2026-03-20 |
| 74 | A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for The Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months. |
CYRUS MAZIDI; | 2026-03-20 |
| 75 | A Randomized, Investigator- and Participant-blinded, Multiple-ascending Dose, Placebo-controlled Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus and Healthy Japanese Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3549492 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 19 weeks for both Part A (Cohorts 1-3) for multiple-ascending doses (MAD), and Part B (Cohorts 4-5) multiple-ascending doses (MAD), for a total of approximately 25 weeks, including screening. |
ELI LILLY | 2026-03-20 |
| 76 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections. |
KEVIN BERMAN; | 2026-03-20 |
| 77 | A Phase 1, Multicenter, Open-Label, Parallel-Design Study to Assess The Pharmacokinetics and Tolerability of A Single Subcutaneous Dose of Eloralintide (LY3841136) in Participants With Mild, Moderate, or Severe Hepatic Impairment and Participants With Normal Hepatic Function PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate how a medicine, LY3841136, works in participants with different levels of liver damage and in participants with healthy liver. The researchers want to see how the medicine is absorbed and used by the body, and if it causes any side effects, in participants with mild, moderate, or severe liver damage, as well as in participants with normal liver function. For each participant, the study will last about 14 weeks, which will include a stay at the clinical research unit for 5 nights. |
THOMAS MARBURY; | 2026-03-20 |
| 78 | A Study to Assess The Use of The Somfit, An Ambulatory Electroencephalogram-Based Digital Health Technology, Compared With Polysomnography to Evaluate Sleep Architecture in Individuals With Asymptomatic or Early Alzheimer’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to compare the results of two different sleep tests in Alzheimer’s patients with no symptoms or early symptoms. Participants will undergo two simultaneous sleep tests (polysomnography) in a sleep laboratory for two nights and one sleep test at home for three nights. For each participant, the study will last at least a week and will last up to three months. |
ELI LILLY | 2026-03-20 |
| 79 | A Phase 1, Open-Label Study to Evaluate The Safety, Biodistribution, Imaging Characteristics, and Radiation Dosimetry of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days. |
ELI LILLY | 2026-03-20 |
| 80 | A Phase 4 Multicenter, Randomized, Open-Label, Interventional Study With Pragmatic Elements Investigating The Effectiveness of Tirzepatide Once Weekly Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes in A Real-World Setting PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks. |
LORNA MCCUNE; | 2026-03-19 |
| 81 | A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate The Efficacy and Safety of LY4268989 (MORF-057) for The Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately 108 weeks, excluding screening. |
INDU SRINIVASAN; | 2026-03-19 |
| 82 | Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer’s disease. |
ELI LILLY | 2026-03-19 |
| 83 | FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating The Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With An FGFR3 Genetic Alteration PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years. |
MARSHALL SCHREEDER; | 2026-03-19 |
| 84 | An Adaptive Two-Stage Bioequivalence Study of Subcutaneous Injections of Mirikizumab Solution in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks. |
KATHLEEN DOISY; | 2026-03-19 |
| 85 | A Phase 4, Prospective, Open-Label, Single Arm Study to Assess The Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months. |
LINDSAY ACKERMAN; | 2026-03-19 |
| 86 | Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis \[JoAS\]) and juvenile psoriatic arthritis (JPsA). |
ELI LILLY | 2026-03-19 |
| 87 | A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for The Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn’s disease and will last at least 62 weeks. |
MORRIS SILVER; | 2026-03-19 |
| 88 | A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared With Mirikizumab in Adults With Moderately to Severely Active Crohn’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn’s disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks. |
MORRIS SILVER; | 2026-03-19 |
| 89 | A Phase 1, Multicenter, Parallel-Design, Single-Dose, Open-Label Study to Evaluate The Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. |
ELI LILLY | 2026-03-19 |
| 90 | A Phase 1b, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled Multiple-Dose Study to Evaluate The Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Brenipatide in Healthy Participants With Overweight or Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity. The study will assess the effects of different doses given as subcutaneous (under the skin) injections. Participation in this study will last about 42 weeks. |
KATHLEEN DOISY; | 2026-03-17 |
| 91 | A Phase 1a/1b Study of The Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years. |
ELI LILLY | 2026-03-13 |
| 92 | A Phase 1, Multicenter, Parallel-Design, Single Dose, Open-Label Study to Evaluate The Pharmacokinetics and Safety of Eloralintide in Participants With Severe Renal Impairment and End Stage Renal Disease (ESRD) Compared With Participants With Normal Renal Function PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin). For each participant, the study will last about 14 weeks, excluding screening. |
PEDRO HERNANDEZ; | 2026-03-13 |
| 93 | A Single- and Multiple-Ascending Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer’s Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive 2 doses of either LY3954068 or placebo administered into the spinal fluid. Participants will have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. The study will last up to approximately 45 weeks for Part A, and 100 weeks for Part B, including the screening period. |
BRANDON LENOX; | 2026-03-12 |
| 94 | Pharmacokinetics of LY3537982 Following A Single Dose in Participants With Renal Impairment Compared With Participants With Normal Renal Function PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to help determine the right dose of LY3537982 in participants with kidney problems, particularly those with severe kidney problems. The study will last about 43 days for each participant. |
ELI LILLY | 2026-03-12 |
| 95 | A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing’s sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond. |
ELI LILLY | 2026-03-12 |
| 96 | A Phase 3, Multicenter, Open-Label Extension Study to Evaluate The Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3 PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria. |
ELI LILLY | 2026-03-11 |
| 97 | A Phase 1 Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it. The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 6 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period. |
OLIVER KLEIN; | 2026-03-11 |
| 98 | A Phase 1, Participant- and Investigator-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Doses of LY3985863 in Healthy Chinese Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY3985863 is tolerated and what side effects may occur in healthy Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. |
ELI LILLY | 2026-03-11 |
| 99 | Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits. |
ELI LILLY | 2026-03-10 |
| 100 | A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine – PIONEER-PEDS2 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits. |
ELI LILLY | 2026-03-10 |
| 101 | An Open-Label, 24-Week Study to Investigate The Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color. |
ELI LILLY | 2026-03-09 |
| 102 | A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months. |
KIMBERLY CRUZ; | 2026-03-09 |
| 103 | A Multiple Ascending Dose Phase 1 Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it. |
PHILIP VAN DAMME; | 2026-03-06 |
| 104 | A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate The Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits. |
ELI LILLY | 2026-03-05 |
| 105 | A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate The Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks. |
SHARRELL COOPER; | 2026-03-05 |
| 106 | A Phase 1b Study of Abemaciclib Plus Darolutamide in Men With Metastatic Castration-Resistant Prostate Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with darolutamide to participants with prostate cancer that has spread after initial treatment. Participation may last up to 32 months. |
ELI LILLY | 2026-03-05 |
| 107 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study With A Separate Open-label Cohort to Evaluate The Efficacy and Safety of Brenipatide As Adjunctive Treatment to Transmucosal Buprenorphine With or Without Naloxone in Early Recovery of Participants With Opioid Use Disorder (RENEW-Op-1) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 144 weeks, maximum potential duration of study participation for a participant in Part B is approximately 116 weeks. The actual duration will vary for each participant depending on the time of enrollment and the overall rate of study enrollment. |
JAMES SULLIVAN; | 2026-03-04 |
| 108 | LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years. |
ELI LILLY | 2026-03-04 |
| 109 | A Study to Evaluate The Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal. Ultrasound will be used to check the stomach content after a test meal. |
NOEL VARGHESE; | 2026-03-04 |
| 110 | A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in The Maintenance of Weight Reduction in Individuals With Obesity PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks. |
ELI LILLY | 2026-03-03 |
| 111 | A Phase 1 Study of Oral LOXO-338, A Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years. |
ELI LILLY | 2026-03-03 |
| 112 | An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for The Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC). |
JAE KIM; | 2026-03-03 |
| 113 | A Single- and Multiple-Ascending Dose Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to explore the safety and any side effects of LY4066708 in healthy participants. The study will also measure how much LY4066708 gets into the bloodstream and the central nervous system and how long it takes the body to remove it. The study will last up to 24 weeks for each participant. |
FIRAS ALMAZEDI; | 2026-03-03 |
| 114 | A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of LY4064912 in Healthy Participants and Participants With Overweight or Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity – global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. |
STEVEN REYNOLDS; | 2026-03-03 |
| 115 | A Phase 1, Investigator- and Participant-Blinded Study to Evaluate The Effect of Retatrutide on Α- and Β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment. |
PATRICK FISCHER; | 2026-03-03 |
| 116 | A Multicenter, Phase 3, Open-Label Study to Investigate The Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative Colitis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC). |
PHILLIP MINAR; | 2026-03-03 |
| 117 | A Phase 1, Participant- and Investigator-Blind, Placebo-Controlled, Multiple-Dose Escalation Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Daily Doses of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks. |
ELI LILLY | 2026-03-03 |
| 118 | A Study to Investigate The Safety, Tolerability, and Pharmacokinetics of A Single Dose of Remternetug in Healthy Chinese Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study will evaluate the safety and tolerability of remternetug when given subcutaneously (SC) (under the skin) to healthy Chinese participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 25 weeks, including screening period. |
CUIBAI WEI; | 2026-03-03 |
| 119 | First-in-Human Study of STX-478, A Mutant-Selective PI3Kα Inhibitor As Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant or imlunestrant) and a CDK4/6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) in participants with HR+ breast cancer. Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy. |
REVA BASHO; | 2026-03-02 |
| 120 | A Master Protocol to Evaluate The Long-Term Safety of Pirtobrutinib PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study. |
AYED AYED; | 2026-03-02 |
| 121 | A First-in-Human, Phase 1a/1b Trial to Assess The Safety, Tolerability and Preliminary Efficacy of LY4175408, An Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years. |
ELI LILLY | 2026-03-02 |
| 122 | A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks. |
SUNILDAT MAHESHWARI; | 2026-03-02 |
| 123 | A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening. |
STEVEN REYNOLDS; | 2026-03-02 |
| 124 | A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate The Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks. |
GIRISH KARAMCHANDANI; | 2026-03-02 |
| 125 | Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib. |
ALVARO ALENCAR; | 2026-03-02 |
| 126 | A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on A Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months. |
DAVID FRANCYK; | 2026-03-02 |
| 127 | A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize The Safety, Tolerability, and Pharmacokinetics of LY4515100 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will include six overnight stays. |
GENE VOSKUHL; | 2026-03-02 |
| 128 | A Phase 1, Open-Label Study to Assess The Relative Bioavailability of Two LY4064809 Formulations in Healthy Adult Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out how much LY4064809 gets into the blood stream and how long it takes the body to get rid of it when it is given as two formulations. For each participant, the study will last about nine weeks. Participants will remain in the clinical research center for about one month. |
ELI LILLY | 2026-03-02 |
| 129 | A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study’s purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years. |
ELI LILLY | 2026-03-02 |
| 130 | A Phase 1/2, Dose-finding Study Investigating The Safety and Efficacy of Pirtobrutinib in Adults With Immune Thrombocytopenia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening. |
ELI LILLY | 2026-03-02 |
| 131 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose. |
ELI LILLY | 2026-02-27 |
| 132 | A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine – The REBUILD-2 Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period. |
ELI LILLY | 2026-02-27 |
| 133 | A Phase 4, Open-Label, Single-Arm, 46-Week Study to Investigate The Safety and Efficacy With Tirzepatide in Adult Indian Participants With Either Type 2 Diabetes or Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes. Participation in the study will last about 46 weeks. |
KARTIKEYA PARMAR; | 2026-02-27 |
| 134 | A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension and Participants With Decreased Estimated Glomerular Filtration Rate PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G. |
AMINA HAGGAG; | 2026-02-23 |
| 135 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating The Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks. |
ELI LILLY | 2026-02-17 |
| 136 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating The Efficacy and Long-Term Safety of Tirzepatide Once Weekly Compared to Placebo in Adults With Type 1 Diabetes and Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months. |
ELI LILLY | 2026-02-17 |
| 137 | A Phase 1 Trial Investigating LY4101174, An Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts – phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years. |
ELI LILLY | 2026-02-11 |
| 138 | A Longitudinal, Prospective Epidemiology Study in Alzheimer’s Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer’s Disease (ANCHOR-AD) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years. |
ALI BAJWA; | 2026-02-10 |
| 139 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate The Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period. |
JAMES KRELL; | 2026-02-10 |
| 140 | A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess The Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months. |
ANDREW SHAROBEEM; | 2026-02-10 |
| 141 | A Phase 3 Multicenter Study to Evaluate The Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU. |
DIEGO VIOLA; | 2026-02-10 |
| 142 | Open-Label, Randomized Study With A Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib. |
DIEGO VIOLA; | 2026-02-10 |
| 143 | JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With A Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer. |
ELI LILLY | 2026-02-06 |
| 144 | A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer. |
ELI LILLY | 2026-02-06 |
| 145 | A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years. |
ELI LILLY | 2026-02-06 |
| 146 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate The Efficacy and Safety of LY3540378 in Adults With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction |
ELI LILLY | 2026-02-05 |
| 147 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, A CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer. |
ELI LILLY | 2026-02-05 |
| 148 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, A CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. |
ELI LILLY | 2026-02-03 |
| 149 | A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate The Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much eloralintide and eloralintide with tirzepatide get into the bloodstream and how long it takes the body to eliminate it. There will be 6 cohorts. The study will last up to approximately 26 weeks, excluding screening for Cohorts A and B, 11 weeks for Cohorts C and D, and 12 weeks for Cohorts E and F. |
ELI LILLY | 2026-01-30 |
| 150 | Zyprexa® Relprevv™ Patient Care Program PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of the Zyprexa Relprevv Patient Care Program is to mitigate the risk of negative outcomes associated with Zyprexa Relprevv post-injection delirium/sedation syndrome (PDSS). |
ELI LILLY | 2026-01-28 |
| 151 | A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine – The REBUILD-1 Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period. |
ELI LILLY | 2026-01-26 |
| 152 | A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer. |
ELI LILLY | 2026-01-26 |
| 153 | A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib As First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After An 8-Week Lead-In Treatment With Erlotinib PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The primary purpose of this study is to compare the efficacy of the study drug LY2875358, given together with erlotinib, against erlotinib, alone. Participants will have Non-Small Cell Lung Cancer (NSCLC) that has advanced to Stage IV. Participants should not have been treated with drugs for Stage IV NSCLC, previously. All participants will get erlotinib alone, for approximately 8 weeks. Participants with radiographic disease control at the end of the erlotinib lead-in study period will be randomly assigned to receive LY2875358 plus erlotinib or erlotinib alone. Participants, who were chosen to receive erlotinib, alone, may cross over to the combination treatment at the time of progression. |
ELI LILLY | 2026-01-26 |
| 154 | A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body. |
ELI LILLY | 2026-01-26 |
| 155 | A Study on Pharmacokinetics of Remternetug Administered Subcutaneously Through An Autoinjector Versus Prefilled Syringe in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes the body to get rid of the remternetug when given as two different formulations. Participation in the study will last approximately 155 days. |
ELI LILLY | 2026-01-23 |
| 156 | A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate The Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants With Type 2 Diabetes During Ramadan PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month. |
ELI LILLY | 2026-01-22 |
| 157 | A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have The PNPLA3 I148M Genotype PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on MASLD and assessment of resolution of liver fibroinflammation. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may last up to 32 weeks for each participant and may include 12 visits in parts A and B. |
ELI LILLY | 2026-01-22 |
| 158 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits. |
ELI LILLY | 2026-01-22 |
| 159 | A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits. |
ELI LILLY | 2026-01-21 |
| 160 | A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer’s Disease PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer’s Disease (AD) over up to 332 weeks. Approximately 800 additional participants will be enrolled in the 12-month Addendum 7 to assess safety of a different titration regimen. |
ELI LILLY | 2026-01-21 |
| 161 | A Single- and Multiple-Ascending Dose Study to Evaluate The Safety and Pharmacokinetics of LY3867070 in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. |
AMINA HAGGAG; | 2026-01-21 |
| 162 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess The Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD). |
ELI LILLY | 2026-01-21 |
| 163 | A Phase 3 Study to Investigate The Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of The Knee: A Randomized, Double-Blind, Placebo-Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks. |
ELI LILLY | 2026-01-21 |
| 164 | Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period. |
ELI LILLY | 2026-01-21 |
| 165 | Long-Term Safety of Pirtobrutinib in Participants From Study J2N-MC-JZNJ With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study – J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years. |
YUQIN SONG; | 2026-01-21 |
| 166 | A Phase 1, Multicenter, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single- and Multiple-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4213663 in Healthy Participants, and Two Open-Label, Multiple-Dose Evaluations of LY4213663 in Patients With Rheumatoid Arthritis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening. |
VISHALA CHINDALORE; | 2026-01-20 |
| 167 | A Four-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B, Part C, and Part D), Multi-Dose, Phase 1 Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec. The study will also evaluate the safety and tolerability of LY3938577 and information about any side effects experienced will be collected. The study will be conducted in four parts (A, B, C, and D). Healthy participants in Part A Period 1 will receive a single dose of LY3938577 or a placebo given via intravenous (IV) infusion. In Part A Period 2, participants will receive a single subcutaneous (SC) dose of either LY3938577 or placebo. Participants in Part B with Type 1 Diabetes Mellitus (T1DM) will receive single doses of either LY3938577 or Insulin Degludec given via IV infusion. Participants in Part C with Type 1 Diabetes Mellitus (T1DM) will receive two doses of either LY3938577 or Insulin Degludec administered SC. Participants in Part D with Type 1 Diabetes Mellitus (T1DM) will be evaluated in 2 … |
OLIVER KLEIN; | 2026-01-20 |
| 168 | Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period. |
ELI LILLY | 2026-01-20 |
| 169 | A Dose-Escalation Phase 1, Investigator- and Participant-Blind, Placebo-Controlled Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3532226 in Participants With Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it following weekly or monthly administration. Part A of the study will last approximately 16 weeks, excluding screening period. Part B of the study will last approximately 20 weeks, excluding the screening period. Part C of the study will last approximately 8 weeks, excluding the screening period. |
ELI LILLY | 2026-01-20 |
| 170 | A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate The Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months. |
ELI LILLY | 2026-01-20 |
| 171 | A Multiple-Ascending Dose Study to Investigate The Safety, Pharmacokinetics, and Pharmacodynamics of LY3537031 in Overweight and Obese Participants and Healthy Volunteers PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 49 weeks excluding a screening period. |
ELI LILLY | 2026-01-20 |
| 172 | A Randomized, Placebo-Controlled, Parallel Study to Investigate The Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during hypoglycemic clamp in participants with Type 2 Diabetes Mellitus (T2DM) following 16 weeks of treatment. |
ELI LILLY | 2026-01-20 |
| 173 | A Phase 2a, Single-Arm Study to Investigate The Efficacy and Safety of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period. |
ELI LILLY | 2026-01-20 |
| 174 | A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Exon 19-Del and Exon 21 L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in Part A before proceeding to Part B. The purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramucirumab in combination with osimertinib in those participants whose disease progressed on ramucirumab and gefitinib and that have T790M – positive metastatic NSCLC. |
ELI LILLY | 2026-01-16 |
| 175 | An Open-Label, Phase 1 Study to Investigate The Comparability of The Pharmacokinetics of Olomorasib (LY3537982) Between Two Capsule Formulations and to Evaluate The Food Effect in Healthy Japanese Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to compare and see how food affects the amount of olomorasib in the blood when olomorasib is taken in two different capsule forms. Participation in the study will last approximately 6 weeks. |
ELI LILLY | 2026-01-16 |
| 176 | PostMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare The Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on A CDK4 & 6 Inhibitor and Endocrine Therapy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond. |
ELI LILLY | 2026-01-16 |
| 177 | A Multiple-Ascending Dose Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3841136 Monotherapy, and LY3841136 in Combination With Tirzepatide, in Japanese Participants With Obesity or Overweight PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits. |
ELI LILLY | 2026-01-16 |
| 178 | A Study to Evaluate The Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal. Ultrasound devices will be used to check the stomach content after a test meal. The study can last approximately 28 weeks. |
NOEL VARGHESE; | 2026-01-16 |
| 179 | A Phase 1, Open-Label Study of The Pharmacokinetics of LY4064809 in Healthy Adult Chinese Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to measure how much LY4064809 gets into the bloodstream and how long it takes the body to eliminate it in healthy participants. It also looks at safety and tolerability in healthy participants. The study drug will be administered orally. The study will last approximately 21 days, excluding screening. |
ELI LILLY | 2026-01-16 |
| 180 | A Phase 1, 2-Part Study to Determine The Effect of Injection Site on The Relative Bioavailability of A Single Subcutaneous Dose of LY3537031 and to Evaluate The Pharmacokinetics of A Single Intravenous Dose of LY3537031 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to find out how much LY3537031 gets into the blood stream and how long it takes the body to get rid of it when it is injected just under the skin in different parts of the body, and when it is injected into a vein, in healthy participants. This study will also look at the safety and tolerability of LY3537031. |
ELI LILLY | 2026-01-16 |
| 181 | A First-in-Human, Phase 1a/1b Trial to Assess The Safety, Tolerability and Preliminary Efficacy of LY4170156, An Antibody-Drug Conjugate Targeting Folate Receptor Α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts – phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years. |
ELI LILLY | 2026-01-14 |
| 182 | A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate The Effect of Tirzepatide on The Reduction of Morbidity and Mortality in Adults With Obesity PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population. |
ELI LILLY | 2026-01-12 |
| 183 | A Phase 1/2 Study of The Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor. |
ELI LILLY | 2026-01-06 |
| 184 | A Bioequivalence Study of Subcutaneous Injections of Citrate-Free Mirikizumab Solution Using A 1-mL Autoinjector and An Investigational 2-mL Autoinjector in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to mirikizumab (reference) solution given via autoinjector. Screening is required within 35 days prior to enrollment. For each participant, the total duration for of the clinical trial will be about 15 weeks, including screening. |
ELI LILLY | 2025-12-30 |
| 185 | A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find a recommended dose level of LY3039478 that can safely be taken by participants with advanced cancer or cancer that has spread to other parts of the body, including but not limited to lymphoma. The study will also explore changes to various markers in blood cells and tissue. Finally, the study will help to document any tumor activity this drug may have. |
ELI LILLY | 2025-12-26 |
| 186 | A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate The Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin And/or SGLT2 Inhibitor PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits. |
ELI LILLY | 2025-12-24 |
| 187 | A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years. |
ELI LILLY | 2025-12-22 |
| 188 | A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction. |
ELI LILLY | 2025-12-22 |
| 189 | [Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: ACCEL is a multicenter, open label phase Ia/Ib/II study of \[Ac-225\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer. |
ELI LILLY | 2025-12-22 |
| 190 | A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening. |
ELI LILLY | 2025-12-18 |
| 191 | A Randomized, Double-Blinded Study to Evaluate The Efficacy and Safety of Mevidalen in Patients With Alzheimer’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits. |
ELI LILLY | 2025-12-17 |
| 192 | A Phase 3, Multicenter, Long-Term Extension Study to Assess The Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with moderate-to-severe atopic dermatitis. This study will last about 68 weeks and may include up to 16 planned visits. If participating in the optional extension as well, the study will last approximately 1 additional year for a total of up to 116 weeks and may include up to 29 scheduled visits. |
ELI LILLY | 2025-12-17 |
| 193 | A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose. |
ELI LILLY | 2025-12-17 |
| 194 | A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate The Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn’s Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn’s disease. |
ELI LILLY | 2025-12-15 |
| 195 | A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate The Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in The Course of Type 2 Diabetes PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early. |
ELI LILLY | 2025-12-12 |
| 196 | The Effect of Imlunestrant on CYP2C8, CYP2C19, CYP2D6, P-gp, and BCRP Activity and The Effect of P-gp Inhibition on Imlunestrant Pharmacokinetics in Healthy Women of Non-childbearing Potential PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and tolerability of imlunestrant will be investigated in female healthy participants of non-childbearing potential. The study will last approximately up to 32 days for each participant excluding the screening period. |
ELI LILLY | 2025-12-12 |
| 197 | An Open-Label, Fixed-Sequence Study to Evaluate The Effect of Multiple Doses of LOXO-292 on The Single Dose Pharmacokinetics of Repaglinide in Healthy Adult Subjects PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to 12 days. |
ELI LILLY | 2025-12-11 |
| 198 | Evaluation of The Effect of Food, Omeprazole, Itraconazole, and Carbamazepine on The Pharmacokinetics of LY3484356 in Healthy Females of Non-Child-Bearing Potential PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the amount of LY3484356 that is found in the blood stream and how long the body takes to get rid of it when given with and without food. Participants are healthy females of non-childbearing potential. The study will also evaluate the tolerability and safety of LY3484356 by collecting the information about any side effects that may occur. The participant’s involvement with the study will last approximately 27 days, not including screening. |
ELI LILLY | 2025-12-11 |
| 199 | An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA). |
CHRISTINE THAI; | 2025-12-09 |
| 200 | A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond. |
ELI LILLY | 2025-12-08 |